Author:
Zhou Xiang,Han Seungbin,Cebulla Nadine,Haertle Larissa,Steinhardt Maximilian J.,Schirmer Daniel,Runau Eva,Flamm Leon,Terhorst Calvin,Jähnel Laura,Vogt Cornelia,Nerreter Silvia,Teufel Eva,Stanojkovska Emilia,Mersi Julia,Munawar Umair,Schindehütte Magnus,Blum Robert,Reinhold Ann-Kristin,Scherf-Clavel Oliver,Rittner Heike L.,Pham Mirko,Rasche Leo,Einsele Hermann,Sommer Claudia,Kortüm K. Martin
Abstract
AbstractWe analyzed single nucleotide polymorphisms (SNPs) in PKNOX1 (rs2839629) and in the intergenic region between PKNOX1 and CBS (rs915854) by Sanger sequencing in 88 patients with multiple myeloma treated with bortezomib. All patients (n = 13) harboring a homozygous mutation in PKNOX1 (rs2839629) also had a homozygous mutated rs915854 genotype. Homozygous mutated genotypes of rs2839629 and rs915854 were significantly enriched in patients with painful peripheral neuropathy (PNP) (P < 0.0001), and homozygous mutated rs2839629 genotype was significantly enriched in patients with pain compared to patients with no pain (P = 0.04). In summary, both SNPs rs2839629 and/or rs915854 may be potential biomarkers predicting an increased risk to develop painful PNP under bortezomib.
Funder
Deutsche Forschungsgemeinschaft
Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg
Dr. Mildred Scheel Stiftung für Krebsforschung
Publisher
Springer Science and Business Media LLC
Subject
Biochemistry (medical),Clinical Biochemistry,Molecular Medicine